Genetic Technologies Share Price - GENE

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
After Hours
Last Trade
Last $ 3.94 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Genetic Technologies Ltd GENE NASDAQ Depository Receipt
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.0706 -1.76% 3.94 4.11 3.8201 3.98 4.0106 23:59:40
Bid Price Ask Price Spread Spread % News
3.57 5.00 1.43 28.6% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume
1,134 395,690  3.95  1,562,459 1,072,664
Last Trade Time Type Quantity Stock Price Currency
17:43:04 30  3.94 USD

Genetic Technologies Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio
 26.68M 6.77M  -5.46M -0.94 - 6.77M
Dividends Per Share Dividend Yield
-  - 0.00% - -

more financials information »

News Genetic Technologies

Loading Messages....

Latest GENE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

GENE Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Genetic Technologies Ltd is an Australia-based molecular diagnostics company which offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.